EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Association of xanthine oxidoreductase inhibitor use with insulin secretory capacity in patients with type 2 diabetes

Atsushi Kitamura, Masafumi Kurajoh iD, Yuya Miki, Yoshinori Kakutani iD, Yuko Yamazaki, Akinobu Ochi, Tomoaki Morioka iD, Katsuhito Mori, Tetsuo Shoji iD, Masanori Emoto

Journal of Diabetes Investigation · 2024

DOI: 10.1111/jdi.14279 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes Investigation, 2024. Verfasst von Atsushi Kitamura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Xanthine Dehydrogenase, Insulin Resistance, Insulin Secretion. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gout Research Foundation of Japan, Gout Research Foundation of Japan 2022.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim/Introduction Xanthine oxidoreductase (XOR) inhibitor treatment, which reduces reactive oxygen species (ROS) production and increases adenosine triphosphate (ATP) synthesis, has been reported to improve glycemic control. The possible protective effects of XOR inhibitor treatment on insulin secretory capacity were investigated in patients with type 2 diabetes. Materials and Methods This retrospective cross‐sectional study included 428 patients with type 2 diabetes. Insulin secretory capacity was assessed based on fasting serum C‐peptide concentration (CPR) and C‐peptide index (CPI) in all subjects, while insulin resistance in non‐insulin users ( n = 312) was determined using the homeostasis model assessment of insulin resistance (HOMA‐IR) index. Results Median values for CPR and CPI in all subjects were 2.4 ng/mL and 1.5, respectively, while that for HOMA‐IR in non‐insulin users was 3.2. The XOR inhibitor users ( n = 72) had significantly ( P < 0.001) higher CPR and CPI levels than non‐users ( n = 356). Multivariable regression analyses showed XOR inhibitor use was positively associated with CPR (β = 0.153, P = 0.001) and CPI (β = 0.144, P = 0.001). Similar results were observed in propensity score analyses. In subgroup analyses of patients with a preserved estimated glomerular filtration rate (≥60 mL/min/1.73 m 2 ) and non‐insulin users, these associations remained significant. Furthermore, the associations were significant in patients with lower (≤6.0 mg/dL) but not with higher (>6.0 mg/dL) uric acid levels ( P for interaction

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Xanthine DehydrogenaseInsulin ResistanceInsulin SecretionHumansMaleFemaleRetrospective StudiesCross-Sectional StudiesMiddle AgedInsulinAgedEnzyme InhibitorsC-PeptideBlood GlucoseBiomarkers

Stichwörter der Autor:innen

XOR inhibitorinsulin secretory capacitytype 2 diabetes

Substanzen

Xanthine DehydrogenaseInsulinEnzyme InhibitorsC-PeptideBlood GlucoseBiomarkers

Autor:innen und Institutionen

  • Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.
  • Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Department of Nephrology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Department of Vascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Vascular Science Center for Translational Research, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.

ORCID-Profile: Masafumi Kurajoh, Yoshinori Kakutani, Tomoaki Morioka, Tetsuo Shoji

Förderung

  • Gout Research Foundation of Japan
  • Gout Research Foundation of Japan 2022

Zitieren

APA

Kitamura, A., Kurajoh, M., Miki, Y., Kakutani, Y., Yamazaki, Y., Ochi, A., Morioka, T., Mori, K., Shoji, T., & Emoto, M. (2024). Association of xanthine oxidoreductase inhibitor use with insulin secretory capacity in patients with type 2 diabetes. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14279

Vancouver

Kitamura A, Kurajoh M, Miki Y, Kakutani Y, Yamazaki Y, Ochi A, et al. Association of xanthine oxidoreductase inhibitor use with insulin secretory capacity in patients with type 2 diabetes. Journal of Diabetes Investigation. 2024. doi:10.1111/jdi.14279

BibTeX
@article{Kitamura2024,
  author = {Kitamura, Atsushi and Kurajoh, Masafumi and Miki, Yuya and Kakutani, Yoshinori and Yamazaki, Yuko and Ochi, Akinobu and Morioka, Tomoaki and Mori, Katsuhito and Shoji, Tetsuo and Emoto, Masanori},
  title = {Association of xanthine oxidoreductase inhibitor use with insulin secretory capacity in patients with type 2 diabetes},
  journal = {Journal of Diabetes Investigation},
  year = {2024},
  doi = {10.1111/jdi.14279}
}
Kostenlos starten →